Skip Navigation

 

Programs

The National Cancer Institute’s (NCI) Clinical Proteomic Technologies for Cancer (CPTC) initiative is composed of three major, integrated programs, all working in tandem to translate protein biomarker discoveries into clinical utility: the Clinical Proteomic Technology Assessment for Cancer (CPTAC) program, the Advanced Platforms and Computational Sciences program, and the Proteomic Reagents and Resources Core. Collaboration is an integral part of the CPTC initiative, and CPTC also encourages industry partnerships through the NCI’s Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) Programs.

This graphic depicts how the different components of CPTC are connected. It illustrates that the four primary components of CPTC are:

1.   CPTAC Centers – Mass Spectrometry and Affinity Platforms
2.   Advanced Proteomic and Computational Sciences
3.   Reagents and Resources Core
4.   Small Business Innovation Research (SBIR)

Together, these programs provide Community Resources that are available for little to no cost.

1.   CPTAC Centers – Mass Spectrometry and Affinity Platforms

The goal of the team-based CPTAC network is to optimize key protein technologies at every step of the biomarker discovery and verification pipelines and make these resources available to the public. This enables comparison of information among laboratories – and significantly improves the quality of biomarker candidates that enter clinical trials as diagnostic tests. There are currently five teams in the CPTAC network, focusing on mass spectrometry and protein microarrays.

For more information see http://proteomics.cancer.gov/programs

CPTAC Centers provide metrics, antibodies and proteins to the scientific community through the Reagents and Resouces Core program. Together with Advanced Proteomic Platforms and Computational Sciences, CPTAC also provides the community with standards, algorithms, ontologies and protocols.

2.   Advanced Proteomic and Computational Sciences

The goal of the Advanced Platforms and Computational Sciences project is to develop next generation tools, technologies and information resources for protein research. This work allows scientists to better understand the difference between proteins from healthy cells versus cancer cells, enabling the development of new ways to detect and treat cancer early.

3.   Reagents and Resources Core

The Clinical Proteomic Reagents and Resources Core serves as a central resource for the scientific community. This team provides researchers with protein mixtures, capture reagents, standard operating procedures, and other resources needed for protein analysis.

For more information see http://proteomics.cancer.gov/programs/reagents_resources

The Reagents and Resources Core makes all resources provided by the CPTAC Network readily available and accessible to the community.

4.   Small Business Innovation Research (SBIR)

The NCI’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Through a variety of funding opportunities, the SBIR & STTR foster research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many other programs designed to prevent, diagnose, and treat cancer.

For more information see http://proteomics.cancer.gov/programs/sbir

The SBIR program utilizes the community resources made availabe by CPTC, and will also provide resources to this iniative.

5.   Community Resources

  • Integrated Searchable Proteomic Database
  • High Quality Biospecimens
  • Standardized Reagents
  • Optimized Technology Platforms
  • Proteomic Standards
  • New Technologies

All resources developed through each of the CPTC programs are made available to the community through the Reagents Data Portal.

Click here to launch the Reagents Data Portal.

Click here for an images version of this graphic.